Overview

Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

Status:
Completed

Trial end date:
2020-07-06

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

PRA Health Sciences

Treatments:

Antibodies, Monoclonal
Durvalumab
Tremelimumab